Cargando…

Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3 + T-regulatory Cell Function and Promotes Antitumor Immunity

Foxp3 + T-regulatory (Treg) cells are known to suppress protective host immune responses to a wide variety of solid tumors, but their therapeutic targeting is largely restricted to their transient depletion or “secondary” modulation, e.g. using anti-CTLA-4 monoclonal antibody. Our ongoing studies of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Liqing, Kumar, Suresh, Dahiya, Satinder, Wang, Feng, Wu, Jian, Newick, Kheng, Han, Rongxiang, Samanta, Arabinda, Beier, Ulf H., Akimova, Tatiana, Bhatti, Tricia R., Nicholson, Benjamin, Kodrasov, Mathew P., Agarwal, Saket, Sterner, David E., Gu, Wei, Weinstock, Joseph, Butt, Tauseef R., Albelda, Steven M., Hancock, Wayne W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264272/
https://www.ncbi.nlm.nih.gov/pubmed/27769803
http://dx.doi.org/10.1016/j.ebiom.2016.10.018
Descripción
Sumario:Foxp3 + T-regulatory (Treg) cells are known to suppress protective host immune responses to a wide variety of solid tumors, but their therapeutic targeting is largely restricted to their transient depletion or “secondary” modulation, e.g. using anti-CTLA-4 monoclonal antibody. Our ongoing studies of the post-translational modifications that regulate Foxp3 demonstrated that the histone/protein acetyltransferase, Tip60, plays a dominant role in promoting acetylation, dimerization and function in Treg cells. We now show that the ubiquitin-specific protease, Usp7, controls Treg function largely by stabilizing the expression and promoting the multimerization of Tip60 and Foxp3. Genetic or pharmacologic targeting of Usp7 impairs Foxp3 + Treg suppressive functions, while conventional T cell responses remain intact. As a result, pharmacologic inhibitors of Usp7 can limit tumor growth in immunocompetent mice, and promote the efficacy of antitumor vaccines and immune checkpoint therapy with anti-PD1 monoclonal antibody in murine models. Hence, pharmacologic therapy with Usp7 inhibitors may have an important role in future cancer immunotherapy.